Travere Therapeutics is a biopharmaceutical company focused on rare diseases, particularly serious kidney and metabolic disorders. Its commercial and late-stage portfolio has centered on treatments such as sparsentan (FILSPARI) for IgA nephropathy and other therapies aimed at underserved rare conditions. The company targets specialist physicians and patients in niche indications where few approved options exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 114.5 | — | -12.8 | — |
| Q3 2025 | 164.9 | — | 25.7 | — |
| Q4 2025 | 129.7 | — | 2.7 | — |
| Q1 2026 | 127.2 | — | -37.1 | — |
| Q2 2026 | 169.6 | 48.2% | -34.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Credit Acceptance Corporation (CACC), Netskope, Inc. (NTSK), Kiniksa Pharmaceuticals International, plc (KNSA), Oruka Therapeutics, Inc. (ORKA), Landstar System, Inc. (LSTR), Liquidia Corporation (LQDA)